Abstract
About 23% of all chronic lymphocytic leukemic (CLL) patients have intractable CLL (ICLL) which is resistant to conventional therapy and has a poor prognosis. The ICLL patients complicate the determination of the efficacy of new therapeutic agents. An in vitro test is needed for the diagnosis of ICLL patients during the first examination.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
